Lexicon Pharmaceuticals | LXRX - Debt


Lexicon Pharmaceuticals reported $99.26M in Debt for its fiscal quarter ending in September of 2023.





Debt Change Date
Abbott USD 12.94B 496M Sep/2025
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Agios Pharmaceuticals USD 44.52M 4.24M Sep/2025
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
AstraZeneca USD 32.63B 207M Sep/2025
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Illumina USD 2.58B 22M Sep/2025
Insmed USD 727.89M 163.33M Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 45.8B 4.97B Sep/2025
Lexicon Pharmaceuticals USD 99.26M 493K Sep/2023
MacroGenics USD 37.01M 238K Sep/2025
MannKind USD 119.91M 73.09M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Moderna USD 734M 7M Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Thermo Fisher Scientific USD 35.68B 451M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
United Therapeutics USD 200M 100M Mar/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024